Abstract:Introduction: Prostate cancer (PCa) is known for its highly diverse clinical behavior, ranging from low-risk, slow-growing tumors to aggressive and life-threatening forms. To avoid over-treatment of low-risk PCa patients, it would be very important prior to any therapeutic intervention to appropriately classify subjects based on tumor aggressiveness. Unfortunately, there is currently no reliable test available for this purpose. The aim of the present study was to evaluate the ability of risk stratification of PCa subjects using an electronic nose (eNose) detecting PCa-specific volatile organic compounds (VOCs) in urine samples. Methods: The study involved 120 participants who underwent diagnostic prostate biopsy followed by robot assisted radical prostatectomy (RARP). PCa risk was categorized as low, intermediate, or high based on the D'Amico risk classification and the pathological grade (PG) assessed after RARP. The eNose's ability to categorize subjects for PCa risk stratification was evaluated based on accuracy and recall metrics. Results: The study population comprised 120 participants. When comparing eNose predictions with PG an accuracy of 79.2% (95%CI 70.8 – 86%) was found, while an accuracy of 74.2% (95%CI 65.4 – 81.7%) was found when compared to D'Amico risk classification system. Additionally, if compared low- versus -intermediate-/high-risk PCa, the eNose achieved an accuracy of 87.5% (95%CI 80.2-92.8%) based on PG or 90.8% (95%CI 84.2–95.3%) based on D'Amico risk classification. However, when using low-/-intermediate versus -high-risk PCa for PG, the accuracy was found to be 91.7% (95%CI 85.2-95.9%). Finally, an accuracy of 80.8% (95%CI72.6-87.4%) was found when compared with D'Amico risk classification. Discussion: The findings of this study indicate that eNose may represent a valid alternative not only for early and non-invasive diagnosis of PCa, but also to categorize patients based on tumor aggressiveness. Further studies including a wider sample population will be necessary to confirm the potential clinical impact of this new technology.

VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach

Analysis of urinary volatile organic compounds for prostate cancer diagnosis: A systematic review

A Study of the Volatile Organic Compounds Exhaled by Lung Cancer Cells in Vitro for Breath Diagnosis

The research on early detection of lung cancer with exhaled volatile organic compounds

Prostate cancer risk stratification via eNose urine odor analysis: a preliminary report

Pilot study for bladder cancer detection with volatile organic compounds using ion mobility spectrometry: a novel urine-based approach

Potentiometric Multisensor System As a Possible Simple Tool for Non-Invasive Prostate Cancer Diagnostics Through Urine Analysis

Electronic Nose for Detecting Lung Cancer Based on Virtual Gas Sensor Array

Human Urinary Volatilome Analysis in Renal Cancer by Electronic Nose

Differences in the Volatilomic Urinary Biosignature of Prostate Cancer Patients as a Feasibility Study for the Detection of Potential Biomarkers

Urinary volatile organic compounds (VOCs) based prostate cancer diagnosis via high-dimensional classification

Quantification of cancer biomarkers in urine using volatilomic approach

Urinary cancer detection by the target urine volatile organic compounds biosensor platform

Towards robust machine olfaction: debiasing GC-MS data enhances prostate cancer diagnosis from urine volatiles

Urinary Volatile Organic Compound Analysis for the Diagnosis of Cancer: A Systematic Literature Review and Quality Assessment

Volatolomic urinary profile analysis for diagnosis of the early stage of lung cancer

Prostate cancer detection using e-nose and AI for high probability assessment

Urinary volatile organic compounds in prostate cancer biopsy pathologic risk stratification using logistic regression and multivariate analysis models

Sniffer dogs can identify lung cancer patients from breath and urine samples

Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine

Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer